INCYIncyte
Price
+31%1YEnd-of-day closes, not the intraday tick.
A rare clean sweep: double-check what the checks can't see
Quality strong, no red flags, undemanding price, growing in the filings, the market undecided.
Incyte is a global biopharmaceutical company engaged in the discovery, development and commercialization of proprietary therapeutics. Our global headquarters is located in Wilmington, Delaware, where we conduct discovery, clinical development and commercial operations. We also conduct clinical development and commercial operations from our European headquarters in Morges, Switzerland, and our other offices across Europe, as well as our Japanese headquarters in Tokyo and our Canadian headquarters in Montreal.
In the company’s own words · 10-K filed Feb 10, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Incyte (INCY) reported revenue of $1.27B in Q1 2026 (quarter ended Mar 31, 2026), up 21% from the same quarter a year earlier. That came with a gross margin of 92% and net income of $303M (24% of revenue). For the full year FY2025, revenue was $5.14B (+21% year on year) and net income $1.29B. Its largest product in Jun 2026 was JAKAFI at $817M, 48% of the disclosed total, well ahead of OPZELURA at 26%. The next results filing is expected around Oct 27, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 31, 2026Incyte Corporation (the “Company”) today announced that it has entered into an agreement with the U.S. Centers for Medicare & Medicaid Services (“CMS”) intended to improve access to medicines for American patients while supporting continued U.S. biopharmaceutical innovation.Other event · Form 8-K
- Jul 28, 2026Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates.Earnings release · press release
- Jul 6, 2026On July 6, 2026, Incyte Corporation (the “Company”) issued a press release announcing it has completed its previously announced acquisition of Vega Therapeutics, Inc., a wholly owned subsidiary of Star Therapeutics LLC (“Vega Therapeutics”)Other event · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Jun 2026 · $1.72BThe company’s own SEC segment disclosure.
- JAKAFI$816.7M48%
- OPZELURA$449.7M26%
- JAKAVI Royalty$124.2M7%
- NIKTIMVO$60.3M4%
- MINJUVIMONJUVI$53.7M3%
- ZYNYZ$49.9M3%
- Other (8)$164.7M10%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Biotechnology
The closest names by size in the same industry